Akums Drugs adj. net profit rises 16% YoY to Rs 66.7 crore in Q2FY25

Akums Drugs and Pharmaceutical, the Delhi-based contract development and manufacturing organisation (CDMO) reported an adjusted net profit of Rs ₹66.7 crore, a 16% year-on-year (YoY) increase from the previous quarter led operational efficiency.

Revenue declined 11.9% YoY to ₹1046.6 crore due to lower active pharmaceutical ingredient (API) prices and fluctuating demand.

Adjusted EBITDA recorded at ₹1,347 million, a 28% drop over the previous quarter, while the company’s adjusted EBITDA margin of 12.9%.


Akums said it remains optimistic that it will stabilize as it expands its footprint and its cash surplus position remains robust at ₹340.6 crore will be instrumental in supporting further investment in R&D and expanding production and business capabilities.

“Short term volatility apart, we continue to see strong secular demand for outsourced drug development and manufacturing," said Sanjeev Jain, managing director.

“Our focus continues to be on the development of innovative products and platforms, exploring more markets towards our larger objective of driving profitable growth. Q2 business performance reflects the muted volume demand and low API prices," Jain added.